[{"id":"78e1680d-703f-4e5f-957a-df94de13cc39","acronym":"","url":"https://clinicaltrials.gov/study/NCT04014881","created_at":"2021-01-18T19:43:13.211Z","updated_at":"2024-07-02T16:36:57.207Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.","source_id_and_acronym":"NCT04014881","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD123 CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 07/06/2019","start_date":" 07/06/2019","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2019-08-07"}]